As we have recently found a novel oncogene, the cancer-upregulated gene 2 (CUG2), which was elevated in a variety of tumor tissues such as the ovary, liver, lung and pancreas, we examined whether reovirus could efficiently induce cytolysis in cancer cells expressing CUG2 and thus be used as a potential cancer therapeutic agent. In this study, we describe experiments in which we use reovirus to treat NIH3T3 cells stably expressing either CUG2 (NIH-CUG2) or vector only (NIH-Vec). NIH-CUG2 cells readily support reoviral proliferation and undergo apoptosis, whereas NIH-Vec cells are highly resistant to reoviral infection and virusinduced apoptosis. This notable result may be explained by the observation that CUG2 expression inhibits PKR activation, leading to reoviral proliferation in nonpermissive NIH3T3 cells. Furthermore, reovirus infection results in almost complete regression of tumorgenic NIH-CUG2 cells in transplanted nude mice. As we found that CUG2 enhances activation of MAPK (ERK, JNK and p38), Src kinase and Ras, we examined whether CUG2 confers reoviral replication independent of the Ras or p38 MAPK signaling pathway. From these experiments we found that either inhibition of p38 MAPK or Ras blocks reoviral proliferation even in the presence of CUG2 but inhibition of ERK, JNK and Src kinase does not, indicating that activation of p38 MAPK and Ras has critical roles in reoviral replication in CUG2-expressing tumor cells. Accordingly, we propose that reovirus can be useful in the treatment of transformed cells expressing CUG2, which is commonly detected in various tumor tissues.
Introduction
To discover new genes that have a crucial role in common tumorigenesis regardless of tissue origin, we analyzed commonly upregulated unknown genes in 242 normal and 300 tumor samples originating from 11 different organ tissues using an Affymetrix gene chip system (Santa Clara, CA). We selected Affymetrix fragments from unidentified genes that exhibited more than a twofold increase in the level of mRNA in at least five different tissues out of 11. An Affymetrix fragment, later named cancer-upregulated gene 2 (CUG2), was identified as a potential candidate gene commonly upregulated in the various tumor tissues. The expression level of CUG2 was notably high in the ovary, liver, lung and pancreas, and mild upregulation was observed in the breast and GI tract cancers such as the colon, retum and stomach. CUG2 was mapped to chromosome 6q22.32, extended about 8.5 kb with a three-exon structure and encoded an 88-amino acid polypeptide. As CUG2 has a nuclear localization sequence, it exists in the nucleus. CUG2 has a very weak homology (27% sequence identities) with downregulator 1 but no notable functional domains have been identified from the peptide sequence. Finally, CUG2 has been shown to posses an oncogenic effect in a transplanted model using NIH3T3 cells expressing CUG2, which was similar to Ras. 1 The human reovirus is a ubiquitous, nonenveloped virus with 10 segments of double-stranded RNA. 2, 3 The virus infection is usually restricted to the upper respiratory and gastrointestinal tracts and is often asymptomatic. [3] [4] [5] However, the reovirus shows dramatic cytolytic activity in certain types of transformed cells. 6, 7 There is a strong body of evidence that Ras-transformed cells are preferentially susceptible to reovirus (type 3 Dearing strain) through inactivation of PKR (dsRNAactivated protein kinase) phosphorylation, 8, 9 and activation of the oncogenic Ras-signaling pathway enhances reoviral oncolytic targeting in various types of human cancers, 10, 11 although our recent study shows that other signaling pathways may also contribute to the susceptibility of a hepatic cancer cell to reoviral replication and oncolysis. 12 Reoviral efficacy has been examined in the treatment of gliomas and other cancers in immunocompetent hosts and has not been shown to produce significant toxicities. 13 These and many other results have led to the current tests of reovirus in several clinical trials. 11, 14, 15 It has also been reported that reoviral oncolysis was associated with the induction of apoptosis in various cancer types. 16 Further investigation has revealed that tumor necrosis factor (TNF)-related apoptosisinducing ligand (TRAIL), a member of the TNF superfamily, is involved in reovirus-induced apoptosis. 17 Caspase 8 and JNK MAPK proteins also participate in apoptotic signaling following reoviral infection. 18 Herein, we explored whether reovirus can be used as a potential cancer therapeutic agent against cancer cells expressing CUG2, which is commonly detected in various tumor tissues. In these studies, we found that CUG2 expression confers reovirus propagation in nonpermissive NIH3T3 cells by the activation of p38 MAPK and Ras. In addition, we showed that reovirus was useful for the treatment of tumor cells expressing CUG2 in vitro and in vivo. On the basis of these combined results, reovirus holds promise for use as an anticancer therapeutic agent in a clinical setting.
Materials and methods
Cell cultures and virus amplification NIH3T3 cells stably expressing vector (NIH-Vec) or CUG2 (NIH-CUG2), and murine L929 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. The Dearing strain of reovirus serotype 3, purchased from the American Type Culture Collection (Manassas, VA), was propagated in L929 cells. The virus was purified as described elsewhere 19 and the viral titer was measured in plaque forming units (PFUs).
Reagents and antibodies PD98059, SP600125 and SB202190 were purchased from Calbiochem (San Diego, CA) to inhibit the activation of MAPK, including ERK, JNK and p38, respectively, and added to cells at different concentrations for 12 h. A farnesyltransferase inhibitor, lonafarnib (SCH66336), was kindly provided by Schering-Plough Research Institute (Kenilworth, NJ). For immunoblotting, anti-Src, death receptor (DR4), Ras and b-tubulin antibodies were obtained from Santa Cruz Biotech (Santa Cruz, CA). ERK, JNK and p38 and their phospho-specific antibodies were acquired from Cell Signaling Biotech (Danvers, MA) and phospho-Src (Tyr418) antibody was purchased from Upstate Biotech (Lake Placid, NY). Glutathione S-transferase (GST)-Raf-RBD fusion protein was obtained from Cytoskeleton (Denver, CO). Anti-DR4 antibody was also purchased from Biolegend (San Diego, CA). Polyclonal anti-reovirus antibody was used for the detection of l, m and s reoviral proteins, as described previously. 2 Western blotting assays Cells were harvested and lysed with lysis buffer (150 mM NaCl, 1% NP-40, 50 mM Tris-HCl (pH 7.5)) containing 0.1 mM Na 2 VO 3 , 1 mM NaF and protease inhibitors (Sigma, St Louis, MO). For immunoblotting, proteins from wholecell lysates were resolved by 10 or 12% SDS polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. Primary antibodies were used at 1:1000 or 1:2000 dilutions, and secondary antibodies conjugated with horseradish peroxidase were used at 1:2000 dilutions in 5% nonfat dry milk. After the final washing, nitrocellulose membranes were exposed for an enhanced chemiluminescence assay using the LAS 3000 (Fuji, Tokyo, Japan).
Active Ras capture assays
To capture GTP-bound Ras from cell lysates, a GSTRaf-RBD fusion protein was used as described elsewhere. 20 The cells were lysed with lysis buffer and glutathione-agarose beads (Clontech, Mountain View, CA) were added to the supernatant and rocked on ice for 30 min to exclude nonspecific binding. After centrifugation, the supernatant was harvested, followed by the addition of GST-Raf-RBD (Cytoskeleton). The solution was rocked on ice for 1 h followed by the addition of glutathione-agarose beads to capture active Ras, which binds to GST-Raf-RBD. After washing three times, the pellet was mixed with 40 ml of 2 Â SDS loading buffer. To detect the captured Ras, immunoblotting was performed with anti-Ras antibody (Santa Cruz).
Tumor growth in nude mice
The NIH-Vec or NIH-CUG2 cells were resuspended in phosphate-buffered saline at a concentration of 6 Â 10 6 cells per ml and about 0.1 ml aliquot of cells from each clone were injected into the flanks of 8-week-old male Balb/c nude mice. Five animals were monitored for each clone and 4 weeks were required for the development of tumors. Reovirus or ultraviolet (UV)-inactivated reovirus was inoculated (1 Â 10 7 PFU per 0.1 ml of phosphatebuffered saline) after tumor formation and tumor size was measured twice a week for another 4 weeks. Histological evaluation of tumor tissues was also performed with hematoxylin-eosin staining.
TUNEL assay and immunohistochemistry of PCNA After killing, tumor tissues were fixed in 4% paraformaldehyde in phosphate-buffered saline, dehydrated through ethanol and xylene, and embedded in paraffin. Sections of 5 mm thickness were obtained and mounted on poly-Llysine-coated glass slides. The ApopAlert DNA fragment CUG2 confers reoviral replication E-H Park et al kit (Clontech) was applied on paraffin sections according to the manufacturer's instructions. Briefly, green fluorescein dUTPs were catalytically added by terminal deoxynucleotidyl transferase at the 3 0 -OH ends of the DNA fragment. The green fluorescein-labeled DNA was counted at 10 random fields using fluorescence microscopy. For evaluation of proliferating cells, the antiproliferating cell nuclear antigen (PCNA) antibody (Santa Cruz) was incubated with the tumor section and the antibody was detected by an ABC-peroxidase solution followed by the addition of the diaminobezidine substrate for visualization.
Statistical analysis
Data were presented as a means±s.e. Student's t-test was used for statistical analysis, with P-value o0.05 defined as significance.
Results

CUG2 renders reoviral replication, leading to cell death in nonpermissive NIH3T3 cells
As we recently identified a novel tumor-associated gene, CUG2, that is commonly activated in various cancers and exhibits high transforming activity, 1 we examined whether reovirus can be used to induce cytolysis in CUG2-expressing cells and thus be used as a potential anticancer drug. To answer this question, we first used a nonpermissive NIH3T3 cell line expressing either the vector only (NIH-Vec) or the vector containing the CUG2 gene (NIH-CUG2).
1 NIH-Vec or -CUG2 cells were infected with reovirus (multiplicity of infection ¼ 0.1) and harvested at 24, 48 and 72 h after infection. Although we did not observe any cytolysis in both NIH-Vec and -CUG2 cells at a low titer of reovirus (Figure 1a) , we did detect a much higher level of reoviral proteins in NIH-CUG2 cells than in NIH-Vec cells at 48 and 72 h after infection, suggesting that CUG2 confers more reoviral replication in nonpermissive NIH3T3 cells (Figure 1b) . In addition, as it has been reported that activation of PKR, a double-stranded RNA-activated protein kinase, reduces host cell protein translation and induces interferon-b production, leading to the establishment of an antiviral status, 21, 22 we examined phosphorylation of PKR during reovirus infection. As shown in Figure 1b , phosphorylation of PKR was detected at 48 and 72 h after infection in NIH-Vec cells, whereas CUG2 expression inhibited the enhancement of PKR phosphorylation during reovirus infection. Next, NIH-Vec or -CUG2 cells were infected with a high titer of reovirus (multiplicity of infection ¼ 10) and examined at 24, 48 and 72 after infection to induce cytolysis of NIH3T3 cells expressing CUG2. As shown in Figure 1c , reovirus sufficiently induced cytolysis of NIH-CUG2 cells at 48 and 72 h after infection, whereas reovirus hardly induced cytolysis of NIH-Vec cells at 72 h after infection. In addition, DR4 was upregulated at 48 and 72 h after reoviral infection in NIH-CUG2 cells but not in NIH-Vec cells, indicating that TRAIL-mediated signaling may be involved in the reovirus-mediated cell death of NIH-CUG2 cells. Accordingly, we believe that CUG2 contributes to the preferential replication of reovirus by suppression of PKR activation, leading to apoptosis through TRAIL signaling. Reovirus infection suppresses growth of tumor cells expressing CUG2 in transplanted nude mice As we observed the oncolytic ability of reovirus in NIH3T3 cells expressing a novel CUG2 oncogene in vitro (Figure 1c) , we examined whether reovirus could still induce cytolysis of NIH-CUG2 in vivo, resulting in the regression of tumor growth in transplanted nude mice. Balb/c nude mice were transplanted with NIH-Vec or -CUG2 cells and tumor formation was inspected twice per week for 4 weeks. We found tumor formation (20 mm 3 ) at the injection site of all the mice transplanted with NIH-CUG2 cells within 4 weeks. 1 When the mice were subsequently administered with UV-inactivated reovirus, tumors developed more aggressively at the site of injection for another 4 weeks (Figure 2a) . However, when the mice bearing NIH-CUG2 tumor cells were treated with live reovirus, the tumor size shrunk. The average size of the NIH-CUG2 tumor infected with live reovirus was approximately sixfold less than those infected with UV-inactivated reovirus at 27 days after infection, which was statistically significant (Po0.05) (Figure 2a ). When we evaluated proliferating cells by PCNA staining of the tumor sections from mice infected with UV-inactivated or live reovirus, we found much more brown colored, PCNA-positive cells in the tumor sections removed from mice infected with UV-inactivated reovirus than that from mice infected with live reovirus (Figure 2b) . Conversely, we found ubiquitous apoptotic cells by TUNEL staining in NIH-CUG2 cells infected with live reovirus but not in NIH-CUG2 cells infected with UV-inactivated reovirus (Figure 2b ). Histological investigation with hematoxylineosin staining also verified tumorigenic morphology in animals infected with UV-inactivated reovirus. In contrast, animals treated with neither UV-inactivated nor live reovirus showed a significant decrease in body weight during the reovirus treatment time period 7 plaque forming units per 0.1 ml of phosphate-buffered saline) or ultraviolet (UV)-inactivated reovirus was administered into the site and tumor size was monitored for another 4 weeks. In addition, the body weight of each mouse was measured. Open circles indicate mice treated with UV-inactivated reovirus, whereas closed circles indicate mice treated with live reovirus. '*' indicates that the difference of tumor volume between live reovirus-and UV-inactivated-treated mice is statistically significant (Po0.05 by Student's t-test). (b) Tumor tissues from mice infected with live and UV-inactivated reovirus were obtained 4 weeks after treatment. As described in the Materials and methods, proliferating cells were determined by anti-proliferating cell nuclear antigen (PCNA) antibodies, which were incubated with the cells for 1 h followed by the addition of the ABC-peroxidase solution. Cells were visualized with the diaminobezidine substrate. Apoptotic cells were detected by the TUNEL assay described in the Materials and methods and green fluorescence-positive cells were counted in 10 random fields under fluorescence microscopy.
CUG2 confers reoviral replication
E-H Park et al (Figure 2c ). In addition, none of the mice injected with NIH-Vec cells developed tumors during 8 week after transplantation (data not shown). These results show that reovirus possess the ability to destroy CUG2-expressing tumor cells in vivo.
Expression of CUG2 enhances the abundance and activities of MAPK and Src kinase As it has been reported that cells resistant to reovirus infection become susceptible after transfection with genes encoding EGFR, v-ErbB or Sos, all of which are capable of activating Ras signaling, 2,23,24 we examined whether CUG2 expression induces upregulation of these genes, which culminates in activation of Src kinase, MAPK and Ras. To address this question, we compared the expression and activity of MAPK and Src kinases, which are related to cellular proliferation between NIH-Vec and -CUG2 cells. As shown in Figure 3a , CUG2 expression induced not only enhanced levels of MAPK, including ERK, JNK and p38, but also elevated phosphorylation of ERK, JNK and p38 MAPK. CUG2 expression also resulted in the elevated expression and activity of Src kinase. On the basis of these results, we wanted to determine whether CUG2 can still provide an environment that facilitates reovirus replication independent of MAPK and Src kinase activities. To test this, NIH-Vec and NIH-CUG2 cells were treated with PD98059 (MEK inhibitor), SP600125 (JNK inhibitor), SB202190 (p38 MAPK inhibitor) or PP2 (Src kinase inhibitor), and reovirus replication was examined by immunoblotting using anti-reovirus antibodies. As shown in Figure 3b , only inhibition of p38 MAPK activity significantly reduced reovirus replication, whereas inhibition of the other kinases, including ERK, JNK and Src, did not affect reovirus replication. In addition, plaque assay showed twofold more viral propagation in the cell treated with reovirus alone than in the cell treated with reovirus and SB202190. These results suggest that the preferential replication of reovirus can be attributed to p38 MAPK activation mediated by CUG2 expression.
CUG2 expression induces abundance and activity of Ras oncoprotein in NIH3T3 cells
As it has also known that Ras activation has a crucial role in reoviral replication, 2, 10 Ras expression and activity were compared in cell lysates from the two cell lines. The amount of Ras protein was higher in NIH-CUG2 cells compared with NIH-Vec cells (Figure 4a ). In addition, the level of active GTP-bound Ras proteins, as detected by GST-Raf-RBD fusion protein binding, was much more abundant in NIH-CUG2 cells compared with NIH-Vec cells (Figure 4a ). Although we observed a large amount of active Ras in NIH-CUG2 cells, we wanted to determine whether CUG2 expression still provides an atmosphere for the preferential replication of reovirus independent of active Ras. To address this question, we treated NIH-CUG2 cells with lonafarnib (SCH66336; a farnesyl transferase inhibitor in clinical trials) to inhibit Ras activity, as lonafarnib and other farnesyltransferase inhibitors have been developed to prevent farnesylation of Ras oncoprotein. 25 As shown in Figure 4b , treatment with lonafarnib (1 mM) did not affect the viability of NIH-CUG2 cells. Reovirus (multiplicity of infection ¼ 10) clearly induced cytolysis of NIH-CUG2 cells at 72 h after infection, whereas lonafarnib significantly prevented reovirus-mediated cytolysis of NIH-CUG2 cells. As , and harvested at 72 h after infection. After proteins from cell lysates were separated on 10% SDS-PAGE, reoviral proteins were detected by immunoblotting using antireovirus polyclonal antibody, which cross-reacts with l, m and s reoviral proteins. In addition, plaques assay was performed from the cell treated with SB and reovirus or reovirus alone.
CUG2 confers reoviral replication E-H Park et al a result of this, over twofold more cells survived in the treatment with reovirus and lonafarnib than the treatment with reovirus alone (Figure 4b ). Lonafarnib treatment also reduced reovirus replication as shown in Figure 4C . In addition, when we performed plaque assay from the cell treated with reovirus or reovirus and lonafarnib, we found that the cell treated with reovirus and lonafarnib produces 2.3 Â 10 6 PFU ml -1 , whereas the cell treated with reovirus alone produces 3.7 Â 10 6 PFU ml -1 . Taken together, we propose that activation of Ras by expression of CUG2 facilitates the preferential replication of reovirus.
Discussion
In a previous study, CUG2 expression was shown to exhibit anchorage-independent growth on soft agar and metastatic features in a cell invasion and migration assay, 1 which is comparable to Ras oncogenecity; however, the tumorigenic mechanism has not yet been revealed. Other studies also reported that the activity of Src kinase was elevated in a variety of human cancers and has been linked with the progression and metastasis of cancer through the VEGF, Akt and ERK pathways. 26, 27 Herein, we observed an abundance of ERK and Src kinase proteins and their elevated kinase activities in NIH-CUG2 cells. On the basis of these observations, we speculate that Src and ERK kinase may be involved in cell invasion and migration mediated by CUG2. However, when considering the clear nuclear localization of CUG2 and the high proportion of basic amino acids in CUG2 (P-value ¼ 11.3), we do not know for certain whether activated Src or ERK kinase directly interacts with CUG2 or not. We are now conducting further studies to identify a binding protein against CUG2 to resolve this question. Moreover, as ERK activity has been reported not to be involved in reoviral replication, 2, 28 we only need to focus on Src kinase. However, inhibition of Src kinase activity does not affect reoviral replication (Figure 3b) .
Although several lines of evidence indicate that Ras-transformed cells are preferentially susceptible to reovirus through the inactivation of PKR phosphorylation, 2, 8 we have recently found that PKR inactivation by Ras activation does not determine reovirus replication in a liver cell expressing hepatitis B virus X, an oncoprotein of the hepatitis B virus. 29 Therefore, we believe that other factors mediated by CUG2 may be involved in reovirus replication. To address this question, we examined whether CUG2 expression depends on p38 MAPK and Figure 4 Activation of Ras is required for reovirus propagation and reovirus-induced cell death. (a) Glutathione S-transferase (GST) or GSTRaf-RBD protein was added to cell lysates from NIH-Vec and -cancer-upregulated gene 2 (CUG2) and active Ras was pulled down with glutathione-agarose beads. The precipitated mixtures were separated on 12% SDS polyacrylamide gel electrophoresis (PAGE) and Ras protein was detected with anti-pan Ras antibody. In addition, the expression level of Ras was examined by immunoblotting using anti-pan Ras antibody. (b and c) NIH-CUG2 cells were treated with lonafarnib (SCH66336; 1 mM), reovirus (multiplicity of infection, MOI ¼ 10) or lonafarnib (1 mM) and reovirus (MOI ¼ 10) for 48 h, and examined under microscopy. The viable cells were counted by Trypan blue exclusion at 48 h after treatment. After proteins from cell lysates prepared at 48 h after treatment were separated on 10% SDS-PAGE, reoviral proteins were detected by immunoblotting using anti-reovirus polyclonal antibody, which cross-reacts with l, m and s reoviral proteins. Lane 1: mock; lane2: lonafarnibtreated cell; lane3: reovirus-treated cell; and lane4: lonafarnib plus reovirus-treated cell. In addition, plaques assay was performed from the cell treated with lonafarnib and reovirus or reovirus alone.
Ras pathways for reovirus replication. From these experiments, we found that reovirus replication was dependent on the activation of p38 MAPK and Ras mediated by CUG2, indicating that CUG2 evokes signals through p38 MAPK and Ras. Furthermore, CUG2 expression repressed the induction of PKR activation during reovirus infection (Figure 1b) , which may support a favorable condition for reovirus replication. We are now investigating the detailed mechanism of how CUG2 activates p38 MAPK and Ras. A new role of Ras in reovirus-induced oncolysis has been revealed elsewhere. A recent study on the role of Ras in reovirus-infected cells has also reported that Ras transformation enhances proteolytic dissemble (uncoating) of the incoming virion, production of infectious virion particle and reovirus release. 30 This study is consistent with our findings that inhibition of Ras activity reduces not only reovirusinduced cytolysis but also reoviral protein synthesis during infection in NIH-3T3 cells expressing CUG2 (Figure 4) . We have also observed that lonafarnib, which is used in clinical phase I and II, inhibits farensylation of H-Ras rather than that of K-Ras or N-Ras in NIH-CUG2 cells (data not shown). In contrast, another study has shown that neither reoviral protein synthesis nor yield was suppressed by depletion of K-RasD12 (constitutive active Ras), although depletion of K-RasD12 abrogates reovirus-induced apoptosis. 31 The study suggests that activation of Ras was required for the apoptotic pathway mediated by reovirus infection. We believe that this discrepancy can be attributed to the cellular context derived from different cell lines.
Accordingly, ubiquitous upregulation of CUG2 mRNA in tumor tissues found from our previous study and an elevated susceptibility of CUG2-expressing cells to reovirus infection could lead to the expanded use of reovirus as a general cancer therapeutic agent.
